Genentech, Inc.

F. Hoffmann-la Roche Ag

Jeffrey Wallin

Deepak Sampath

Lori Friedman

Marcia Belvin

Priti Hegde

Kui Lin

Mallika Singh

Michelle Nannini

Elizabeth Punnoose

Klaus Hoeflich

Premal Patel

Ulka Vijapurkar

Leisa Johnson

Sonal Patel

Klaus P Hoeflich

Iris T Chan

John Prescott

The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R, R, R, R, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use

Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents. 

Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer

Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Combinations of phosphoinositide 3-kinase inhibitor compounds chemotherapeutic agents, and methods of use

Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use

Growing community of inventors

South San Francisco, CA, United States of America

Jeffrey Wallin